ZOGENIX
At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products. We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. Our lead product candidate, sumatriptan DoseProâ„¢, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain.
ZOGENIX
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2006-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.zogenix.com
Total Employee:
251+
Status:
Active
Contact:
1-858-259-1165
Email Addresses:
[email protected]
Total Funding:
1.52 B USD
Technology used in webpage:
Domain Not Resolving EnFlow
Similar Organizations
Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals develops and commercializes small molecule drugs for the treatment of central nervous system disorders.
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Aeovian Pharmaceuticals
Aeovian Pharmaceuticals aims to discover, develop, and commercialize therapeutics for the treatment of rare and age-related diseases.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
BionPharma
BionPharma develops and commercializes affordable quality generics and builds strong and effective partnerships.
GlaxoSmithKline
GlaxoSmithKline develops and markets products in the areas of pain relief, respiratory, digestive health, oral health, nutrition and skin.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
Tandem Diabetes Care
Tandem diabetes care provides products that empower both people with diabetes and those who care for them.
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2019-08-26 | Modis Therapeutics | Modis Therapeutics acquired by Zogenix | 250 M USD |
| 2014-10-27 | Brabant pharma | Brabant pharma acquired by Zogenix | 35 M USD |
Investors List
HealthCare Royalty Partners
HealthCare Royalty Partners investment in Post-IPO Debt - Zogenix
Silicon Valley Bank
Silicon Valley Bank investment in Debt Financing - Zogenix
Thomas, McNerney & Partners
Thomas, McNerney & Partners investment in Venture Round - Zogenix
Oxford Finance LLC
Oxford Finance LLC investment in Debt Financing - Zogenix
Chicago Growth Partners
Chicago Growth Partners investment in Venture Round - Zogenix
Oxford Finance LLC
Oxford Finance LLC investment in Venture Round - Zogenix
Scale Venture Partners
Scale Venture Partners investment in Venture Round - Zogenix
Domain Associates
Domain Associates investment in Venture Round - Zogenix
Clarus Ventures
Clarus Ventures investment in Venture Round - Zogenix
Abingworth
Abingworth investment in Venture Round - Zogenix
Official Site Inspections
http://www.zogenix.com
- Host name: 76.76.21.21
- IP address: 76.76.21.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Zogenix"
Zogenix - Crunchbase Company Profile & Funding
Zogenix may be growing as indicated by the acquisition of FINTEPLA® (fenfluramine) in March 2022, which is an approved product, suggesting an …See details»
UCB Completes Acquisition of Zogenix, Inc.
Mar 7, 2022 Broadens and builds upon UCB’s role as a leader in, and our continued commitment to, addressing unmet needs of people living with epilepsy Total transaction value …See details»
UCB to acquire Zogenix
Jan 19, 2022 Brussels (Belgium) and Emeryville, CA (USA), 19 January 2022 - Regulated information – Inside information – UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) …See details»
Performance - UCB
Cash flow from financing activities had an outflow of € 818 million, which includes the full repayment of the bullet term loan facility agreement for the acquisition of Ra Pharmaceuticals, Inc. (US$ - 605 million) and the partial repayment of the …See details»
Zogenix Company Profile - Office Locations, Competitors ... - Craft
Mar 4, 2022 Zogenix $81.69 m in annual revenue in FY 2021. See insights on Zogenix including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Zogenix IncExecutive & Employee Information - GlobalData
The following section provides information on Zogenix Inc’s senior management, executives, CEO and key decision makers and their roles in the organization. For more insight into Zogenix …See details»
Zogenix - Raised $149M Funding from 13 investors - Tracxn
Mar 10, 2025 List of Zogenix's institutional investors. HealthCare Royalty Partners, located in Stamford (United States), made their first investment in Zogenix on Jun 30, 2011 in its Post …See details»
Zogenix, Inc. : culture | LinkedIn
Zogenix, Inc. | 9 629 abonnés sur LinkedIn. A global pharmaceutical company developing rare disease therapies | Zogenix is a global pharmaceutical company passionate about taking on …See details»
Zogenix International Ltd. - Drug pipelines, Patents, Clinical trials ...
Explore Zogenix International Ltd. with its drug pipeline, therapeutic area, technology platform, 16 clinical trials, and 14 literature, Disease Domain:Endocrinology and Metabolic Disease, …See details»
ZOGENIX INTERNATIONAL LIMITED [Windsor And Maidenhead / …
ZOGENIX INTERNATIONAL LIMITED [Windsor And Maidenhead / United Kingdom of Great Britain and Northern Ireland] located in WINDSOR AND MAIDENHEAD ENGLAND, United …See details»
How did UCB close its $1.9B deal to buy Zogenix and …
Feb 1, 2022 The rest of Zogenix’s executive vice presidents—CFO Michael Smith, General Counsel Shawnte Mitchell, CMO Bradley Galer, M.D., and CDO Gail Farfel—will each receive between $1.53 million and ...See details»
UCB Completes Acquisition of Zogenix, Inc. - PR Newswire
Mar 7, 2022 UCB Completes Acquisition of Zogenix, Inc. - Broadens and builds upon UCB's role as a leader in, and our continued commitment to, addressing unmet needs of people living …See details»
Dr. Stephen Farr Appointed As CEO Of Zogenix (ZGNX) To Lead …
May 1, 2015 SAN DIEGO, April 27, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the …See details»
Zogenix Announces Acquisition of Modis Therapeutics, Inc.
Aug 26, 2019 --Zogenix, Inc., a global pharmaceutical company developing rare disease therapies, today announced that it has entered into a definitive agreement to acquire Modis …See details»
优时比19亿美元收购Zogenix，获得癫痫新药 - Pharmcube
⌈ByDrug医药新闻摘要⌋ 2022-01-21 07:49，医药魔方：1月19日，UCB宣布已与Zogenix公司达成最终协议，以每股26美元收购Zogenix所有的流通股。 此外，如果Fintepla (芬氟拉明)治 …See details»
The European Commission Approves Zogenix’s FINTEPLA® …
EMERYVILLE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, announced today that …See details»
Working at Zogenix - Glassdoor
Zogenix is committed to developing and commercializing therapies for central nervous system disorders that address specific clinical needs for people living with rare diseases ... We …See details»
Working at Zogenix: Employee Reviews | Indeed.com
Reviews from Zogenix employees about Zogenix culture, salaries, benefits, work-life balance, management, job security, and more.See details»
Chasing GW's Epidiolex, Zogenix finally wins FDA nod for rare …
Jun 26, 2020 RELATED: After Dravet hiccup, Zogenix's Fintepla prevails in phase 3 Lennox-Gastaut test Fintepla didn’t exactly enjoy a smooth sail toward its final FDA nod. The agency …See details»
Zogenix, Inc. et al v. Apotex Inc. et al | RPX Insight - RPX Corp
Parties, patents and docket of Zogenix International Ltd. v. Apotex Inc. and 2 other defendants (1:21-cv-01252) from District of Delaware filed on 08/30/2021 and closed on 11/28/2023See details»